Efficiency and Target Derepression of Anti-miR-92a: Results of a First in Human Study.

Wesley Tyler Abplanalp,Ariane Fischer,David John,Andreas M. Zeiher,Willy Gosgnach,Hélène Darville,Rusty L. Montgomery,Linda A Pestano,Guillaume Allée,Isabelle Paty,Francoise Fougerousse,Stefanie Dimmeler

Efficiency and Target Derepression of Anti-miR-92a: Results of a First in Human Study.

2020

Wesley Tyler Abplanalp
Ariane Fischer
David John
Andreas M. Zeiher
Willy Gosgnach
Hélène Darville
Rusty L. Montgomery
Linda A Pestano
Guillaume Allée
Isabelle Paty
Francoise Fougerousse
Stefanie Dimmeler

MicroRNA (miRNA) inhibition is a promising therapeutic strategy in several disease indications. MRG-110 is a locked nucleic acid-based antisense oligonucleotide that targets miR-92a-3p and experime...

Keywords:

Derepression
Locked nucleic acid
Cancer research
Molecular biology
antisense oligonucleotide
therapeutic strategy
first in human
Biology
Single cell sequencing
microRNA

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations